These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32553315)

  • 1. Ocular adverse events in drug sensitive TB patients on daily fixed dose combination anti-TB drugs: A record review study from Kerala, India.
    Manu MS; Mehta K; Das M; Balakrishnan S; Sunil Kumar M; Rakesh PS; Sindhu MP; Valamparampil MJ; Neena PS; Satyanarayana S
    Indian J Tuberc; 2020 Apr; 67(2):216-221. PubMed ID: 32553315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.
    Lienhardt C; Cook SV; Burgos M; Yorke-Edwards V; Rigouts L; Anyo G; Kim SJ; Jindani A; Enarson DA; Nunn AJ;
    JAMA; 2011 Apr; 305(14):1415-23. PubMed ID: 21486974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs.
    Suzuki Y; Miwa S; Shirai M; Ohba H; Murakami M; Fujita K; Suda T; Nakamura H; Hayakawa H; Chida K
    Chest; 2008 Nov; 134(5):1027-1032. PubMed ID: 18583516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of content of anti-TB drugs supplied at centres of the Revised National TB Control Programme in Tamil Nadu, India.
    Ramachandran G; Chandrasekaran V; Hemanth Kumar AK; Dewan P; Swaminathan S; Thomas A
    Trop Med Int Health; 2013 Sep; 18(9):1141-1144. PubMed ID: 23937703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R; Heilig CM; Tapy JM; Bozeman L; Kyle RP; Hamilton CD; Bock N; Narita M; Wing D; Hershfield E; Goldberg SV;
    Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
    Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ; Perng RP
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberculosis control programme guidelines--treatment regimens.
    Durrheim DN; Belt EL
    S Afr Med J; 1996 Oct; 86(10):1293-4. PubMed ID: 8955740
    [No Abstract]   [Full Text] [Related]  

  • 11. Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination.
    Wang HF; Wang R; O'Gorman M; Crownover P; Naqvi A; Jafri I
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1596-601. PubMed ID: 24200275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-month, four-drug preventive therapy for inactive pulmonary tuberculosis.
    Goldberg SV; Duchin JS; Shields T; Nolan CM
    Am J Respir Crit Care Med; 1999 Aug; 160(2):508-12. PubMed ID: 10430721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
    Yee D; Valiquette C; Pelletier M; Parisien I; Rocher I; Menzies D
    Am J Respir Crit Care Med; 2003 Jun; 167(11):1472-7. PubMed ID: 12569078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From Scylla to Charybdis: Fixed drug combinations for tuberculosis and increased ethambutol-induced optic neuropathy in India.
    Bhargava A; Sahoo NK; Das AV; Tyagi M; Kammari P; Sheth J; Kurada J; Shukla S
    Indian J Ophthalmol; 2022 Aug; 70(8):3073-3076. PubMed ID: 35918975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens.
    Blomberg B; Fourie B
    Drugs; 2003; 63(6):535-53. PubMed ID: 12656652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
    J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar.
    Al-Shaer MH; Elewa H; Alkabab Y; Nazer LH; Heysell SK
    BMC Infect Dis; 2018 Aug; 18(1):384. PubMed ID: 30089476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform.
    Cao J; Mi Y; Shi C; Bian Y; Huang C; Ye Z; Liu L; Miao L
    Biochem Biophys Res Commun; 2018 Mar; 497(2):485-491. PubMed ID: 29454961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
    Zierski M; Bek E
    Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.